GRAIL, Inc.
Grail Inc's stock surged 11.3% to $120.81 after an FDA panel voted that the benefits of its Galleri multi-cancer detection test outweigh risks for adults 50+. The panel also unanimously supported its safety. Analysts raised price targets and maintained positive ratings. The FDA's final decision is pending, with some uncertainty remaining. The move is company-specific, with broader markets down.
GRAIL Inc.'s (GRAL) Galleri multi-cancer early detection test received a favorable vote from an FDA panel, advancing its approval process. The test aims to detect cancer early by analyzing DNA fragments in blood. The panel unanimously supported its safety, with mixed votes on effectiveness and benefit-risk. GRAIL claims Galleri detects 4-7x more cancers than standard screening. The FDA's final decision is expected soon. GRAL stock was halted at $108.52 ahead of the vote.
Grail (GRAL) received FDA panel backing for its Galleri blood test to detect cancer, according to Bloomberg. The panel voted 6-4 on effectiveness and agreed on safety. Baird raised its price target to $118 from $86, while Mizuho noted FDA briefing documents were favorable to approval. Analysts maintain a hold rating, citing priced-in regulatory upside.
Over the past 7 days, AlphAI's AI scored 19 news stories mentioning GRAL (GRAIL, Inc.). Coverage has skewed bullish: 17 bullish, 2 neutral, and 0 bearish.
Recent GRAL coverage spans regulation and insider activity.
In the last 30 days, GRAL insiders filed 13 SEC Form 4 transactions — no purchases and 13 sales ($7.5M). The most active reporter was Ofman Joshua J., Chief Executive Officer, with 9 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive regulatory outcome likely fuels further upside pending final FDA approval.
Positive panel recommendation likely lifts sentiment and may trigger a price rally ahead of final FDA decision.
Positive regulatory signal likely to boost Grail's stock price.
Insider sale by the CEO may signal reduced confidence, potentially pressuring the stock short term.
Potential FDA approval could lift Grail's valuation and drive significant price upside.
AlphAI scores every news story that mentions GRAL with an AI model for sentiment and relevance, and aggregates insider trades from GRAIL, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Grail Inc's stock surged 11.3% to $120.81 after an FDA panel voted that the benefits of its Galleri multi-cancer detection test outweigh risks for adults 50+. The panel also unanimously supported its safety. Analysts raised price targets and maintained positive ratings. The FDA's final decision is pending, with some uncertainty remaining. The move is company-specific, with broader markets down.
2 min readGRAIL Inc.'s (GRAL) Galleri multi-cancer early detection test received a favorable vote from an FDA panel, advancing its approval process. The test aims to detect cancer early by analyzing DNA fragments in blood. The panel unanimously supported its safety, with mixed votes on effectiveness and benefit-risk. GRAIL claims Galleri detects 4-7x more cancers than standard screening. The FDA's final decision is expected soon. GRAL stock was halted at $108.52 ahead of the vote.
2 min readGrail (GRAL) received FDA panel backing for its Galleri blood test to detect cancer, according to Bloomberg. The panel voted 6-4 on effectiveness and agreed on safety. Baird raised its price target to $118 from $86, while Mizuho noted FDA briefing documents were favorable to approval. Analysts maintain a hold rating, citing priced-in regulatory upside.
1 min readOfman Joshua J. (Chief Executive Officer) sold 61,452 shares of GRAIL, Inc. (GRAL) at an average of $97.74 ($92.32–$110.00, $6.01M total) across 8 trades on 2026-09-21 under a Rule 10b5-1 trading plan.
1 min readThe FDA panel discussed Grail's (GRAL) blood test for early cancer detection, Galleri. The stock was halted during the meeting, which is a step toward FDA approval. The test aims to screen asymptomatic people, potentially improving treatment outcomes.
2 min readGrail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.
6 min readGRAIL (GRAL) rose 33.7% to $107.97 after FDA staff raised no major concerns about its Galleri cancer test. The FDA panel will vote on approval for adults 50+. Galleri detected 35% of cancers in PATHFINDER 2 and 31.6% in NHS-Galleri. The test's specificity was above 99.7%. GRAL reported $42.6M in Q2 test revenue and a net loss of $110.2M.
2 min readGRAIL Inc. (GRAL) shares rose above $100 ahead of an FDA advisory committee review of its Galleri cancer detection test on September 23, 2026. The panel will assess safety, effectiveness, and risks. GRAL stock has fluctuated, reaching a 52-week high of $118.84 and a low of $73 in 2026. It closed at $107.97 after a 33% rally.
2 min readGrail (GRAL) shares rose 32% after FDA posted briefing documents suggesting a positive view of its cancer-detecting blood test, Galleri, ahead of a key meeting. The test's safety and effectiveness will be evaluated for early cancer screening.
1 min readGrail Inc. (GRAL) shares surged 36.56% after FDA documents highlighted the clinical benefits of its Galleri multi-cancer early detection test. The FDA will review the test's approval on September 23. Grail reported Q2 2026 revenue of $44.7M, up 26% YoY, with a net loss of $110.2M. The company also secured $110M from Samsung for expansion in Asia.
3 min read
